Latest
Hot
Both $Eli Lilly and Co (LLY.US)$stock and $Novo-Nordisk A/S (NVO.US)$stock dipped below their 50-day line in late October — a bearish sign — as investors await a Food and Drug Administration decision on LLY's potential weight-loss drug and focus on NVO's Supply of Wegovy.
Lilly's diabetes drug Mounjaro, a GLP-1 agonist, is expected to be approved for weight loss before the end of the year. Novo Nordisk currently leads the pack w...
Lilly's diabetes drug Mounjaro, a GLP-1 agonist, is expected to be approved for weight loss before the end of the year. Novo Nordisk currently leads the pack w...
+1
21
1
$Amgen (AMGN.US)$ is scheduled to announce Q2 earnings results on 06 August (Tuesday) after the market close.
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...
+2
14
Jim Cramer says insurance companies will pay for ‘revolutionary’ weight-loss drugs for their members
CNBC’s Jim Cramer on Monday emphasized his belief that GLP-1 drugs primarily used to treat diabetes and obesity and the companies that make them, like Eli Lilly and Novo Nordisk, will be very valuable.
“At the end of the day, the use cases are tested. And for millions of people, it’ll be cheaper for the insurance companies to shell out for the new weight-loss drugs than to let their morbidly obes...
“At the end of the day, the use cases are tested. And for millions of people, it’ll be cheaper for the insurance companies to shell out for the new weight-loss drugs than to let their morbidly obes...
7
As revenue from COVID-19 products evaporates, $Pfizer (PFE.US)$ hopes to get a slice of the emerging weight loss market.
Analysts say the upcoming data on Pfizer's experimental weight loss drug, danuglipron, will be crucial for the company's competition with major players like $Novo-Nordisk A/S (NVO.US)$ and $Eli Lilly and Co (LLY.US)$ in the emerging weight loss market.
Investors are eagerly awaiting Pfizer's phase 2 trial data...
Analysts say the upcoming data on Pfizer's experimental weight loss drug, danuglipron, will be crucial for the company's competition with major players like $Novo-Nordisk A/S (NVO.US)$ and $Eli Lilly and Co (LLY.US)$ in the emerging weight loss market.
Investors are eagerly awaiting Pfizer's phase 2 trial data...
5
1
Citi and J.P. Morgan analysts commented bullishly on obesity treatment market, predicting a 'turbocharged' outlook based on presented data. They expect the market to hit $71 billion by 2032 with Novo and Eli Lilly owning about 90%.
Columns Novo Nordisk Q3 2023 Financial Report Review | Wegovy Supply Limited, Expected Stable Stock Price
On November 2nd, Novo Nordisk announced detailed Q3 2023 financial results, with group sales of DKK 58.731 billion, up 2% from the consensus estimate of DKK 57.810 billion, and operating profit of DKK 26.913 billion, up 4% from the consensus estimate of DKK 25.813 billion.
JPM released a report on Novo Nordisk's financial results on November 2nd.
I. Valuation
Stock Rating: Overweight
Recent Closing P...
JPM released a report on Novo Nordisk's financial results on November 2nd.
I. Valuation
Stock Rating: Overweight
Recent Closing P...
+3
$Eli Lilly and Co (LLY.US)$ stock jumped in early November after the Food and Drug Administration signed off on its new weight-loss drug, a rival to $Novo-Nordisk A/S (NVO.US)$
Recently, Novo said a weekly shot of Ozempic helped stave off renal impairment and reduced the risk of death due to kidney or cardiovascular disease in patients with type 2 diabetes and chronic kidney disease. Earlier this year, Novo said patients who took Wegov...
Recently, Novo said a weekly shot of Ozempic helped stave off renal impairment and reduced the risk of death due to kidney or cardiovascular disease in patients with type 2 diabetes and chronic kidney disease. Earlier this year, Novo said patients who took Wegov...
5
$CareDx (CDNA.US)$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
$Sangamo Therapeutics (SGMO.US)$ Some new info has come to light! besides my interest in 2024. This little tidbit could bring some attention sooner? ( Sangamo and Pfizer plan to present updated data, of which a summary of the accepted abstract is located below, from the Phase 1/2 Alta study in a platform presentation at the 65th American Society of Hematology Annual Meeting & Exposition on December 11, 2023. )![]()
Concerns about potential impacts of GLP-1 drugs on the demand for diabetes device therapies may be misplaced, as illustrated by strong Q3 results from diabetes tech leaders like Abbott, Dexcom, and Insulet.
2
green225 : 413.00